PitchSend

Investor Presentaiton

Core Operating Profit Increased by 10.1 Bn JPY (Increased by 10.0 Bn JPY excl. forex impact) FY2022 Q1 Results 34.4 Revenue 70.5 Cost of Sales SG&A Expenses 34.1 Revenue +70.5 incl. forex impact of +11.5 Cost of Sales +15.6 15.6 Daiichi-Sankyo (Bn JPY) Increase in cost of sales due to the revenue increase SG&A Expenses +34.1 Increase in expenses related to Enhertu due to an increase in profit share of gross profit with AstraZeneca R&D Expenses Forex Impact 0.8 Forex Impact +11.5 (Profit Decreased) 11.5 Cost of Sales +3.3 SG&A Expenses +5.2 FY2023 Q1 Results 44.5 R&D Expenses +3.0 Positive Factors Negative Factors 6

View entire presentation